IL204958A0 - Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs) - Google Patents

Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs)

Info

Publication number
IL204958A0
IL204958A0 IL204958A IL20495810A IL204958A0 IL 204958 A0 IL204958 A0 IL 204958A0 IL 204958 A IL204958 A IL 204958A IL 20495810 A IL20495810 A IL 20495810A IL 204958 A0 IL204958 A0 IL 204958A0
Authority
IL
Israel
Prior art keywords
mglurs
modulators
metabotropic glutamate
glutamate receptors
tetrazole derivatives
Prior art date
Application number
IL204958A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Erwan Arzel
Louise Edwards
Methvin Isaac
Donald A Mcleod
Abdelmalik Slassi
Tao Xin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL204958(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Erwan Arzel, Louise Edwards, Methvin Isaac, Donald A Mcleod, Abdelmalik Slassi, Tao Xin filed Critical Astrazeneca Ab
Publication of IL204958A0 publication Critical patent/IL204958A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL204958A 2007-10-19 2010-04-08 Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs) IL204958A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98129407P 2007-10-19 2007-10-19
PCT/SE2008/051170 WO2009051556A1 (en) 2007-10-19 2008-10-17 Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs)

Publications (1)

Publication Number Publication Date
IL204958A0 true IL204958A0 (en) 2010-11-30

Family

ID=40567640

Family Applications (1)

Application Number Title Priority Date Filing Date
IL204958A IL204958A0 (en) 2007-10-19 2010-04-08 Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs)

Country Status (21)

Country Link
US (1) US7960422B2 (enExample)
EP (1) EP2231647A4 (enExample)
JP (1) JP2011500673A (enExample)
KR (1) KR20100090777A (enExample)
CN (1) CN101896480A (enExample)
AR (1) AR068921A1 (enExample)
AU (1) AU2008312055A1 (enExample)
BR (1) BRPI0818448A2 (enExample)
CA (1) CA2703425A1 (enExample)
CL (1) CL2008003085A1 (enExample)
CO (1) CO6321281A2 (enExample)
CR (1) CR11376A (enExample)
DO (1) DOP2010000119A (enExample)
EA (1) EA201000654A1 (enExample)
IL (1) IL204958A0 (enExample)
MX (1) MX2010004272A (enExample)
PE (1) PE20090875A1 (enExample)
TW (1) TW200934771A (enExample)
UY (1) UY31403A1 (enExample)
WO (1) WO2009051556A1 (enExample)
ZA (1) ZA201002694B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
DK2610258T3 (da) * 2007-10-19 2014-11-10 Boehringer Ingelheim Int Substituerede piperidindihydrothienopyrimidiner
JP5563466B2 (ja) 2007-10-19 2014-07-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ピペラジノ−ジヒドロチエノピリミジン誘導体
CN101827853A (zh) 2007-10-19 2010-09-08 贝林格尔.英格海姆国际有限公司 杂环取代的哌嗪子基-二氢噻吩并嘧啶
MX2011003011A (es) 2008-09-22 2011-09-01 Cayman Chem Co Compuestos de multiheteroarilo como inhibidores de prostaglandina d sintasa hematopoyetica y su uso para tratar enfermedades mediadas por prostaglandina d2.
EP2379531A1 (en) * 2008-12-18 2011-10-26 AstraZeneca AB Processes for the manufacture of 3-{4-methyl-5- [ (ir) -1- (2- (3-methylphenyl) -2h-tetrazol-5-yl) -ethoxy]-4h- [1,2, 4]triazol-3-yl} -pyridine, 4-methyl-3-methylthio-5- (3- pyridyl)-l,2,4-triazole, and (ir) -1- [2- (3-methylphenyl) -2h- tetrazol-5-yl]ethanol
AU2010255552A1 (en) 2009-06-05 2012-01-12 Oslo University Hospital Hf Azole derivatives as Wtn pathway inhibitors
EP2649063A1 (en) 2010-12-08 2013-10-16 Oslo University Hospital HF Triazole derivatives as wnt signaling pathway inhibitors
EP2685977A1 (en) 2011-03-18 2014-01-22 Novartis AG COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
CN106032377A (zh) * 2015-03-12 2016-10-19 天津药物研究院有限公司 四氮唑类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663332A (en) 1985-10-10 1987-05-05 Hoffman-La Roche Inc. 5-substituted N-alkylated tetrazoles
US5492919A (en) 1991-08-03 1996-02-20 Smithkline Beecham P.L.C. 5-HT4 receptor antagonists
DE10023430A1 (de) 2000-05-12 2001-11-15 Bayer Ag Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
ATE396186T1 (de) 2001-10-04 2008-06-15 Merck & Co Inc Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5
US7592337B2 (en) 2002-03-12 2009-09-22 Merck & Co., Inc. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
CN1894241A (zh) * 2002-08-09 2007-01-10 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
BRPI0507501A (pt) * 2004-02-18 2007-06-26 Astrazeneca Ab composto, composição farmacêutica, uso do composto, método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
SG149900A1 (en) 2004-02-18 2009-02-27 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
AU2005214379B2 (en) * 2004-02-18 2012-03-22 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200811156A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators IV
TW200811157A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I

Also Published As

Publication number Publication date
CA2703425A1 (en) 2009-04-23
KR20100090777A (ko) 2010-08-17
ZA201002694B (en) 2011-03-30
BRPI0818448A2 (pt) 2015-05-12
PE20090875A1 (es) 2009-08-08
DOP2010000119A (es) 2010-05-31
JP2011500673A (ja) 2011-01-06
CL2008003085A1 (es) 2009-10-09
US20090131454A1 (en) 2009-05-21
AU2008312055A1 (en) 2009-04-23
AR068921A1 (es) 2009-12-16
EP2231647A4 (en) 2011-08-31
EP2231647A1 (en) 2010-09-29
CR11376A (es) 2010-07-19
US7960422B2 (en) 2011-06-14
UY31403A1 (es) 2009-05-29
CO6321281A2 (es) 2011-09-20
MX2010004272A (es) 2010-04-30
WO2009051556A1 (en) 2009-04-23
CN101896480A (zh) 2010-11-24
TW200934771A (en) 2009-08-16
EA201000654A1 (ru) 2010-12-30

Similar Documents

Publication Publication Date Title
IL204958A0 (en) Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs)
IL201995A0 (en) Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
ZA200710280B (en) Novel heterocyclic compounds as positive allosteric modulators of metabotropic glutamate receptors
IL179692A0 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
IL187186A0 (en) Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
ZA200906241B (en) Novel tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors
AP2516A (en) 2-Pyridine carboxamide derivatives as sodium channel modulators
IL200922A0 (en) 8-oxy-quinoline derivatives as bradykinin b2 receptor modulators
PT2134685E (pt) Derivados de índole não substituídos na posição 7 como inibidores de mcl-1
ATE502938T1 (de) Pyridinderivate als s1p1/edg1-rezeptormodulatoren
IL189617A0 (en) Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
IL219149A0 (en) Novel oxime derivatives and thier use as allosteric modulators of metabotropic glutamate receptors
EP2097384A4 (en) INDOZALYL SULFOMNAMIDE DERIVATIVES USEFUL AS MODULATORS OF GLUCOCORTICOIDS
IL210067A0 (en) Pyridinylpiperazin derivatives useful as modulators of dopamine d3 receptors
IL190740A0 (en) Chromenones and their use as modulators of metabotropic glutamate receptors
ZA200903235B (en) Novel Triazinedione Derivatives as Gaba-b receptor modulators
EP2229167A4 (en) MINERALCORTICOIDREZEPTORMODULATOREN
IL204888A0 (en) Thiophene - 2 - carboxamide derivatives as modulators of ccr9 receptor
HK1148282A (en) Tetrazole derivates as modulators of metabotropic glutamate receptors (mglurs)
ZA200710278B (en) Substituted Oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
HK1142061A (en) Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
GB0507793D0 (en) Allosteric modulators of glutamate receptors
AU2007907046A0 (en) Modulation of GABAbeta receptors